Shanghai Xuerong Bio-Tech faces potential control change

Shanghai Xuerong Bio-Technology faces a potential change in control, prompting a cautionary note from CCXI. The company's controlling shareholder, Yang Yongping, is planning a transaction that could result in a new entity holding 25.33% of Xuerong's total share capital. The potential acquirer is a private technology services enterprise. CCXI had previously downgraded Xuerong's main credit rating from A+ to A with a negative outlook. The rating agency notes that the transaction requires regulatory approval and is subject to significant uncertainty. CCXI will continue to monitor the situation and its potential impact on Xuerong's credit profile.